News Sentiment

ACRV sentiment intelligence

Acrivon Therapeutics, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 61 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.96 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

80/100 classification confidence.

Company focus 53

directly relevant articles

Source quality 6

high-authority source matches

Trend context Trend inactive

+14.0% over one week, +32.4% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?

Market Reaction

Price moving ahead of tone

65/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 80/100 classification
One-week reaction 14.0% Price confirming higher
Trend fit Trend inactive 32.4% over four weeks
Fair value -58.6% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 19
Neutral 39
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 53
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 11
Market source 9
TradingView 6
simplywall.st 4
Quiver Quantitative 4
Finviz 3
Barron's 3
Seeking Alpha 2

Event Lens

What the news is about

Classified themes
Market update 34
Earnings 20
Analyst action 5
Balance sheet 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 61
Investing.com Direct company coverage

Acrivon Therapeutics’ SWOT analysis: stock shows promise in cancer pipeline

Acrivon Therapeutics, a clinical-stage biopharmaceutical company, is advancing a pipeline of precision oncology candidates for difficult-to-treat cancers, with its lead program, ACR-368, showing an improved objective response rate of 52% in serous endometrial cancer. The company

Tone
Positive 71/100
Event
Market update
Published
22 May 2026 16:09
Source
Investing.com
GlobeNewswire Direct company coverage

Acrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation Summit

Acrivon Therapeutics announced its President and CEO, Peter Blume-Jensen, M.D., Ph.D., will participate in a virtual fireside chat at TD Cowen’s 7th Annual Oncology Innovation Summit on May 26, 2026. The company is a clinical-stage oncology firm developing precision medicines gui

Tone
Positive 65/100
Event
Market update
Published
22 May 2026 03:39
Source
GlobeNewswire
Stock Titan Direct company coverage

Acrivon CEO to join TD Cowen cancer innovation webcast May 26

Acrivon Therapeutics (Nasdaq: ACRV) CEO, Peter Blume-Jensen, M.D., Ph.D., will participate in a virtual fireside chat at TD Cowen’s 7th Annual Oncology Innovation Summit on May 26, 2026, at 9:00 a.m. ET. The company, a clinical-stage biotechnology firm, will discuss its precision

Tone
Positive 65/100
Event
Market update
Published
21 May 2026 11:41
Source
Stock Titan
Stock Titan Direct company coverage

Acrivon Therapeutics (ACRV) leaders receive new RSU and stock grants

Acrivon Therapeutics, Inc. (ACRV) reported equity awards to senior leaders, including President and CEO Peter Blume-Jensen and EVP Kristina Masson, in the form of Restricted Stock Units (RSUs) and common stock grants. The awards include 72,706 RSUs and 180,095 shares of Common St

Tone
Neutral 50/100
Event
Market update
Published
21 May 2026 03:09
Source
Stock Titan